Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Low Doses of Thalidomide (Thal) in Low Risk MDS with Transfusion-Dependant Anemia: The GFM THAL-SMD-200 Trial.

J. Tamburini, C. Elie, D. Vassilief, M.C. Quarre, O. Beyne-Rauzy, M. Gardembas, A. Aouba, C. Berthou, L. Sanhes, A. Guerci, A. Stamatoullas, F. Bauduer, J.J. Sotto, L. Legros, S. Vaultier, P. Fenaux, F. Dreyfus, D. Bouscary

Blood (2006) 108 (11): 2673.

https://doi.org/10.1182/blood.V108.11.2673.2673

Published: 2006

Journal Articles

Allogeneic Stem Cell Transplantation (allo-SCT) from a HLA Identical Sibling for CR1 AML Patients Aged above 55 Years Old after a Reduced Intensity Conditioning: A Survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Didier Blaise, Zina Chir, Michel Attal, Jean-Henri Bourhis, Jean-Jacques Sotto, Jean-Michel Boiron, Noel Milpied, Jean-Yves Cahn, Bernard Rio, Bruno Lioure, Francois Guilhot, C. Berthou, Agnes Buzyn, Mauricette Michallet

Blood (2005) 106 (11): 1140.

https://doi.org/10.1182/blood.V106.11.1140.1140

Published: 2005

Journal Articles

Thalidomide for the Treatment of Low Risk Myelodysplasia.

D. Bouscary, MD-PhD, M. C. Quarre, MD, D. Vassilief, MD, O. Beyne Rouzy, MD, A. Aouba, MD, C. Berthou, MD, C. Gardembas, MD, L. Sanhes, MD, A. Guerci, MD, B. Mahe, MD, A. Stamatoullas, MD, F. Bauduer, MD, J. J. Sotto, MD, L. Legros, MD-PhD, S. Vaultier, ARC, P. Fenaux, MD-PhD, F. Dreyfus, MD

Blood (2004) 104 (11): 1438.

https://doi.org/10.1182/blood.V104.11.1438.1438

Published: 2004

Journal Articles

Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study

E Solary, B Witz, D Caillot, P Moreau, B Desablens, JY Cahn, A Sadoun, B Pignon, C Berthou, F Maloisel, D Guyotat, P Casassus, N Ifrah, Y Lamy, B Audhuy, P Colombat, JL Harousseau

Blood (1996) 88 (4): 1198–1205.

https://doi.org/10.1182/blood.V88.4.1198.bloodjournal8841198

Published: 1996

Journal Articles

Granzyme B and perforin lytic proteins are expressed in CD34+ peripheral blood progenitor cells mobilized by chemotherapy and granulocyte colony-stimulating factor

C Berthou, JP Marolleau, C Lafaurie, A Soulie, L Dal Cortivo, JF Bourge, M Benbunan, M Sasportes

Blood (1995) 86 (9): 3500–3506.

https://doi.org/10.1182/blood.V86.9.3500.bloodjournal8693500

Published: 1995

Journal Articles

Cord blood T lymphocytes lack constitutive perforin expression in contrast to adult peripheral blood T lymphocytes

C Berthou, S Legros-Maida, A Soulie, A Wargnier, J Guillet, C Rabian, E Gluckman, M Sasportes

Blood (1995) 85 (6): 1540–1546.

https://doi.org/10.1182/blood.V85.6.1540.bloodjournal8561540

Published: 1995

NARROW

Low Doses of Thalidomide (Thal) in Low Risk MDS with Transfusion-Dependant Anemia: The GFM THAL-SMD-200 Trial.

Allogeneic Stem Cell Transplantation (allo-SCT) from a HLA Identical Sibling for CR1 AML Patients Aged above 55 Years Old after a Reduced Intensity Conditioning: A Survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Thalidomide for the Treatment of Low Risk Myelodysplasia.

Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study

Granzyme B and perforin lytic proteins are expressed in CD34+ peripheral blood progenitor cells mobilized by chemotherapy and granulocyte colony-stimulating factor

Cord blood T lymphocytes lack constitutive perforin expression in contrast to adult peripheral blood T lymphocytes

Email alerts

ASH Publications

American Society of Hematology

Low Doses of Thalidomide (Thal) in Low Risk MDS with Transfusion-Dependant Anemia: The GFM THAL-SMD-200 Trial.

Allogeneic Stem Cell Transplantation (allo-SCT) from a HLA Identical Sibling for CR1 AML Patients Aged above 55 Years Old after a Reduced Intensity Conditioning: A Survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Thalidomide for the Treatment of Low Risk Myelodysplasia.

Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study

Granzyme B and perforin lytic proteins are expressed in CD34+ peripheral blood progenitor cells mobilized by chemotherapy and granulocyte colony-stimulating factor

Cord blood T lymphocytes lack constitutive perforin expression in contrast to adult peripheral blood T lymphocytes

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only